{
    "clinical_study": {
        "@rank": "77170", 
        "arm_group": [
            {
                "arm_group_label": "LY2605541 - Cohort A (Arm)", 
                "arm_group_type": "Experimental", 
                "description": "Each healthy participant will receive 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the arm in 1 of 3 treatment periods."
            }, 
            {
                "arm_group_label": "LY2605541 - Cohort A (Thigh)", 
                "arm_group_type": "Experimental", 
                "description": "Each healthy participant will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh in 1 of 3 treatment periods."
            }, 
            {
                "arm_group_label": "LY2605541 - Cohort A (Abdomen)", 
                "arm_group_type": "Experimental", 
                "description": "Each healthy participant will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall in 1 of 3 treatment periods."
            }, 
            {
                "arm_group_label": "LY2605541 - Cohort B (Abdomen)", 
                "arm_group_type": "Experimental", 
                "description": "Each elderly participant will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will include two groups (cohorts) of participants:\n\n      In Group A, this study will look at the amount of LY2605541 that is present in the body\n      after it is injected in 3 different locations in the body of the same participant. At least\n      16 days will pass between each injection.\n\n      In Group B, the study will look at how the body absorbs, distributes, and gets rid of\n      LY2605541 in participants over age 65.\n\n      Participants may enroll in only one group."
        }, 
        "brief_title": "A Study of LY2605541 in Healthy Participants and in the Elderly", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cohort A: are overtly healthy male or female participants, as determined by medical\n             history and physical examination, aged \u226518 to \u226455 years of age\n\n          -  Cohort B: are male or female elderly (\u226565 years of age) participants that are overtly\n             healthy, or have stable, chronic medical conditions [including Type 2 Diabetes\n             Mellitus (T2DM)] that, in the investigator's opinion, will not significantly alter\n             the disposition of the drug, will not place the participant at increased risk by\n             participating in the study, and will not interfere with interpretation of the data\n\n          -  Male participants agree to use a reliable method of birth control during the study\n             and for 3 months following the last dose of the investigational product\n\n          -  Female participants are women of child-bearing potential who test negative for\n             pregnancy at the time of screening based on a urine pregnancy test and agree to use a\n             reliable method of birth control during the study and for 1 month following the last\n             dose of the investigational product\n\n          -  Female participants are post-menopausal women, or women not of child-bearing\n             potential due to surgical sterilization (at least 3 months after surgical\n             hysterectomy, or at least 3 months after bilateral oophorectomy or bilateral tubal\n             ligation/occlusion with or without hysterectomy) confirmed by medical history, or\n             menopause\n\n          -  Have a body mass index (BMI) of 18.5 to 40 kilogram per meter square (kg/m^2),\n             inclusive at time of admission for Period 1\n\n          -  Have given written informed consent approved by Lilly and the ethical review board\n             (ERB) governing the site\n\n        Exclusion Criteria:\n\n          -  Are participants that intend to start a change in diet or lose weight during the\n             study; participants will be expected to maintain their approximate current weight\n             throughout the study\n\n          -  Are excessive smokers (>10 cigarettes per day); participants who smoke less than or\n             equal to (\u2264)10 cigarettes per day must be able to stop smoking whilst resident at the\n             clinical research unit (CRU)\n\n        Healthy Participants - Cohort A\n\n          -  Have Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), or a fasting\n             blood glucose (BG) greater than (>) 110 milligrams per deciliter (mg/dL) [6.1\n             millimoles per liter (mmol/L)] with a glycated hemoglobin (HbA1c) of >6.2%\n\n          -  Intend to use over-the-counter medication within the 7 days or prescription\n             medication within 14 days prior to dosing (apart from contraceptive medication,\n             vitamin/mineral supplements, occasional paracetamol, thyroxine replacement therapy,\n             and hormone replacement therapy). Antihypertensive and lipid lowering agents are\n             permitted, but must have been administered at stable dose(s) for at least 1 month\n\n        Elderly Participants - Cohort B\n\n          -  Have T1DM\n\n          -  Are T2DM participants that require insulin treatment, or have a HbA1c of >10%\n\n          -  Have started new chronic medication(s) or changed the dose of an existing chronic\n             medication <1 month prior to dosing. Participants are permitted to continue ongoing\n             chronic medications (for example antihypertensive agents, aspirin, non-steroidal\n             anti-inflammatory drugs, lipid lowering agents, thyroxine, hormone replacement\n             therapy, and/or oral anti-diabetic if participants have T2DM). Other stable chronic\n             conditions may be permitted if deemed acceptable by the investigators and Lilly\n             clinical pharmacologist or clinical research physician"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818245", 
            "org_study_id": "12152", 
            "secondary_id": "I2R-MC-BIDF"
        }, 
        "intervention": {
            "arm_group_label": [
                "LY2605541 - Cohort A (Arm)", 
                "LY2605541 - Cohort A (Thigh)", 
                "LY2605541 - Cohort A (Abdomen)", 
                "LY2605541 - Cohort B (Abdomen)"
            ], 
            "description": "Administered SC.", 
            "intervention_name": "LY2605541", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "July 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Effect of Injection Site on the Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of LY2605541 in Healthy Subjects, and Impact of Body Mass Index and Age on the Pharmacokinetics of LY2605541", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 216 hours postdose"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum Plasma Concentration (Cmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 216 hours postdose"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Elderly Participants (\u226565 Years of Age) Versus Participants \u226455 Years of Age (Abdominal Injection)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 216 hours postdose"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum Plasma Concentration (Cmax): Elderly Participants (\u226565 Years of Age) Versus Participants \u226455 Years of Age (Abdominal Injection)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 216 hours postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818245"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamics: Total Amount of Glucose Infused (Gtot): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours post clamp procedure in all treatment periods"
            }, 
            {
                "measure": "Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours post clamp procedure in all treatment periods"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}